[go: up one dir, main page]

US20140294795A1 - Nutritional Composition - Google Patents

Nutritional Composition Download PDF

Info

Publication number
US20140294795A1
US20140294795A1 US13/852,472 US201313852472A US2014294795A1 US 20140294795 A1 US20140294795 A1 US 20140294795A1 US 201313852472 A US201313852472 A US 201313852472A US 2014294795 A1 US2014294795 A1 US 2014294795A1
Authority
US
United States
Prior art keywords
mcg
vitamin
composition
present
selenium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/852,472
Inventor
Houn Simon Hsia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/852,472 priority Critical patent/US20140294795A1/en
Publication of US20140294795A1 publication Critical patent/US20140294795A1/en
Priority to US15/205,786 priority patent/US10117902B2/en
Priority to US16/156,990 priority patent/US10653733B2/en
Priority to US16/875,805 priority patent/US10946052B2/en
Priority to US17/200,056 priority patent/US11253561B2/en
Priority to US17/675,181 priority patent/US11576940B2/en
Priority to US18/079,155 priority patent/US12029769B2/en
Priority to US18/763,681 priority patent/US20240350569A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/32—Tin compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to nutritional compositions useful for increasing the efficacy of cancer therapies, including chemotherapy, radiation and target therapies; and more specifically to nutritional compositions to promote anti-tumor activity.
  • Cancer is one of the most deadly diseases of all centuries. Preventing and treatment of cancer is, therefore, and extremely important endeavor for centuries to pursue. Much progress has been made over the last 50 years for the treatment of cancer, including chemotherapeutic, radiation and most recently, target therapies. A major shortcoming of these therapeutic treatments is their harmful effects to the human system since, in many cases, the practice of such therapies causes severe weight loss, hair loss, and in many cases, death.
  • the present invention overcomes the shortcomings of the art of cancer therapy by providing compositions that work together to enhance the immune system such that the health of the cancer patient is not compromised by the harsh effects of the cancer therapies, and as a result, can overcome such effects, resulting in more efficient cancer remedial therapeutic treatments.
  • the present invention provides nutritional compositions that are employed as oral supplementation to the human diet.
  • the compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer.
  • the present invention teaches a combination of specific nutritients suitable for oral consumption by the human body.
  • the compositions of the present invention when orally ingested on a daily basis, in combination with or without therapeutic treatments for cancer, specifically chemotherapy, target therapy and radiation therapy, work in a synergistic fashion together to aid the cancer patient in eliminating the cancer, healing of the cancer and recovery from the cancer.
  • the compositions of the present invention may also be ingested on a daily, or periodic basis to help prevent cancer.
  • compositions of the present invention Although the mechanism of action of the compositions of the present invention are not well understood, many cases have been reported of cancer patients benefiting from the use of the present invention in combination with the therapeutic treatments for cancer. It is believed that the key ingredients of the present invention work synergistically together to aid in the anti-neoplastic processes.
  • the recent publication entitled “Reduction of Splenic Immunosuppressive Cells and Enhancement of Anti-Tumor Immunity by Synergy of Fish Oil and Selenium Yeast” Wang h, Chan Y-L, et al. (2013) PLoS ONE 8(1):e52912. Dol:10.1371/journal.pone.005912) provides evidence that indeed the compositions of the present invention provide said synergistic action, and also that the compositions taught by the present invention are novel and useful for the prevention and treatment of cancer.
  • compositions include as preferred embodiment selenium.
  • the preferred form of selenium is selenium yeast.
  • the preferred amount of selenium yeast is from about 5 mcg to about 500 mcg, and more preferred between about 10 mcg to about 250 mcg, and most preferably from between 25 mcg to about 150 mcg.
  • the preferred selenium yeast are Saccharomyces cerevisiae, Saccharomyces exiguous, Saccharomyces pastorianus, Saccharomyces boulardii, Saccharomyces bayanus, Saccharomyces eubayanus, Saccharomyces florentinus, Saccharomyces fragilis.
  • the preferred fish oil has an EDA/DHA ratio of from between 1 part EPA to about 5 parts DHA, and from between 5 parts EPA to 1 part DHA, and more preferably from about 2 parts EPA to 1 part DHA, and most preferably from about 3 parts EPA to about 2 parts DHA.
  • the EPA/DHA content of the fish oil preparations of the present invention are from between 10% to about 90%, more preferably from between 30% to about 70% and most preferably from about 40% to about 60%.
  • the preferred amounts of fish oil EPA/DHA preparation of the present invention is from 0.50 mg to about 1.5 g, and more preferably between 250 mg to about 1000 mg, and most preferably between 350 mg to about 750 mg.
  • Beta Carotene Another essential component of the present invention is Beta Carotene.
  • the preferred form of beta carotene is the naturally occurring form.
  • the preferred amount is between 500 iu and 10,000 iu, and more preferably between 1500 iu and 7500 iu, and most preferably between about 1000 iu and 3000 iu.
  • Resverotrol is another important nutrient of the present invention.
  • the preferred form of Resverotrol is from plan extract.
  • the preferred amount of Resverotrol in the extract is from between 50% to about 98%, and most preferably about 95%.
  • the preferred amount of Resverotrol extract to be employed in the present invention is from about 5 mg to about 1500 mg, and more preferably from about 50 mg to about 300 mg, and most preferably from about 75 mg to about 150 mg.
  • Vitamin D3 may be added to the nutritional compositions of the present invention.
  • the preferred form of Vitamin D3 is Cholecalciferol.
  • the preferred amount of Vitamin D3 is from between 50 iu and 3000 iu, and more preferably between from about 70 iu to about 500 iu, and most preferably from about 100 iu to about 250 iu.
  • Vitamin K Another prime nutrient that may be included in the embodiments of the present invention is Vitamin K.
  • the preferred form of Vitamin K is Phytonadione.
  • the preferred amount of Vitamin K is between 2.5 mcg to about 250 mcg, more preferably from between 15 mcg to about 100 mcg, and most preferably between 20 mcg to about 75 mcg.
  • Vitamin B6 Another nutrient important to the efficacy of the present invention is Vitamin B6.
  • the preferred form of Vitamin B6 is Pyridoxine hydrochloride.
  • the preferred amount is between 0.1 mg to about 100 mg, most preferably between about 0.5 mg to about 25 mg, and most preferably from about 0.75 mg to about 10 mg.
  • Vitamin B 12 may be included in the present invention.
  • the preferred form of Vitamin B12 is Cyanocobalamin.
  • the preferred amount of Vitamin B12 is between about 0.3 mcg to about 900 mcg, most preferably between about 0.75 mcg to about 50 mcg, and most preferably between 1 mcg and 10 mcg.
  • Folic Acid Another nutrient that is important to the present invention is Folic Acid.
  • the preferred amount of Folic Acid is between about 25 mcg to about 1000 mcg, most preferably between about 100 mcg to about 750 mcg, and most preferably between 200 mcg and 400 mcg.
  • the mineral Zinc is important to include in the present invention.
  • the preferred amount of Zinc is between about 0.65 mcg to about 4000 mcg, most preferably between about 1 mcg to about 400 mcg, and most preferably between 3 mcg and 50 mcg.
  • the mineral Chromium is important to include in the present invention.
  • the preferred form of Chromium is from yeast.
  • the preferred amount of Chromium is between about 30 mcg to about 3000 mcg, most preferably between about 50 mcg to about 500 mcg, and most preferably between 25 mcg and 100 mcg.
  • the mineral Molybdenum is important to include in the present invention.
  • the preferred form of Molybdenum is from yeast.
  • the preferred amount of Molybdenum is between about 2.5 mcg to about 1000 mcg, most preferably between about 10 mcg to about 130 mcg, and most preferably between 15 mcg and 60 mcg.
  • the amino acid glutamine is important to include in the present invention.
  • the preferred amount of glutamine is between about 2.1 g to about 250 g, most preferably between about 11 g to about 135 g, and most preferably between 10 g and 50 g.
  • the amino acid arginine is important to include in the present invention.
  • the preferred amount of argenine is between about 0.71 g to about 25 g, most preferably between about 3.0 g to about 15 g, and most preferably between 5 g and 13 g.
  • the amino acid taurine is important to include in the present invention.
  • the preferred amount of taurine is between about 1.1 g to about 29 g, most preferably between about 2.3 g to about 15 g, and most preferably between 3 g and 11 g.
  • the amino acid lysine is important to include in the present invention.
  • the preferred amount of taurine is between about 0.81 g to about 49 g, most preferably between about 5.3 g to about 35 g, and most preferably between 6 g and 18 g.
  • Coenzyme Q-10 Another important nutrient is Coenzyme Q-10.
  • the preferred amount of Coenzyme Q-10 is from about 30 mg to about 1000 mg, most preferably from between about 50 mg to 300 mg, and most preferably between about 60 mg to about 180 mg.
  • the above ingredients were admixed and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
  • the above ingredients were admixed and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
  • the above ingredients were admixed and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
  • the above ingredients were admixed and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
  • the above ingredients were admixed and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
  • the above ingredients were admixed and shaken until homogeneous blend was obtained.
  • the blended composition was poured into 250 mL of water, mixed and then consumed via drinking.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals.

Description

    FIELD OF THE INVENTION
  • The present invention relates to nutritional compositions useful for increasing the efficacy of cancer therapies, including chemotherapy, radiation and target therapies; and more specifically to nutritional compositions to promote anti-tumor activity.
    • BACKGROUND OF THE INVENTION
  • Cancer is one of the most deadly diseases of all mankind. Preventing and treatment of cancer is, therefore, and extremely important endeavor for mankind to pursue. Much progress has been made over the last 50 years for the treatment of cancer, including chemotherapeutic, radiation and most recently, target therapies. A major shortcoming of these therapeutic treatments is their harmful effects to the human system since, in many cases, the practice of such therapies causes severe weight loss, hair loss, and in many cases, death.
  • It is believed that one of the major causes of the ill-effects of cancer therapies is that they tax the human immune system. A healthy and potent human immune system is very important to combat the ill-effects of the cancer therapies. The present invention overcomes the shortcomings of the art of cancer therapy by providing compositions that work together to enhance the immune system such that the health of the cancer patient is not compromised by the harsh effects of the cancer therapies, and as a result, can overcome such effects, resulting in more efficient cancer remedial therapeutic treatments.
    • SUMMARY OF THE INVENTION
  • The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer.
  • It is a prime objective of the present invention to provide nutritive compositions that when used in combination with radiation, target or chemotherapy, provide for an increased activity in combating neoplastic growth.
  • It is another objective of the present invention to provide for anti-neoplastic effects by dietary supplementation utilizing specific forms of nutrients such as selenium yeast and fish oil.
  • It is another objective of the present invention to provide for compositions that help prevent cancer.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention teaches a combination of specific nutritients suitable for oral consumption by the human body. The compositions of the present invention when orally ingested on a daily basis, in combination with or without therapeutic treatments for cancer, specifically chemotherapy, target therapy and radiation therapy, work in a synergistic fashion together to aid the cancer patient in eliminating the cancer, healing of the cancer and recovery from the cancer. The compositions of the present invention may also be ingested on a daily, or periodic basis to help prevent cancer.
  • Although the mechanism of action of the compositions of the present invention are not well understood, many cases have been reported of cancer patients benefiting from the use of the present invention in combination with the therapeutic treatments for cancer. It is believed that the key ingredients of the present invention work synergistically together to aid in the anti-neoplastic processes. The recent publication entitled “Reduction of Splenic Immunosuppressive Cells and Enhancement of Anti-Tumor Immunity by Synergy of Fish Oil and Selenium Yeast” (Wang h, Chan Y-L, et al. (2013) PLoS ONE 8(1):e52912. Dol:10.1371/journal.pone.005912) provides evidence that indeed the compositions of the present invention provide said synergistic action, and also that the compositions taught by the present invention are novel and useful for the prevention and treatment of cancer.
  • These compositions include as preferred embodiment selenium. The preferred form of selenium is selenium yeast. The preferred amount of selenium yeast is from about 5 mcg to about 500 mcg, and more preferred between about 10 mcg to about 250 mcg, and most preferably from between 25 mcg to about 150 mcg. The preferred selenium yeast are Saccharomyces cerevisiae, Saccharomyces exiguous, Saccharomyces pastorianus, Saccharomyces boulardii, Saccharomyces bayanus, Saccharomyces eubayanus, Saccharomyces florentinus, Saccharomyces fragilis.
  • Another essential ingredient of the present invention is fish oil. The preferred fish oil has an EDA/DHA ratio of from between 1 part EPA to about 5 parts DHA, and from between 5 parts EPA to 1 part DHA, and more preferably from about 2 parts EPA to 1 part DHA, and most preferably from about 3 parts EPA to about 2 parts DHA. The EPA/DHA content of the fish oil preparations of the present invention are from between 10% to about 90%, more preferably from between 30% to about 70% and most preferably from about 40% to about 60%. The preferred amounts of fish oil EPA/DHA preparation of the present invention is from 0.50 mg to about 1.5 g, and more preferably between 250 mg to about 1000 mg, and most preferably between 350 mg to about 750 mg.
  • Another essential component of the present invention is Beta Carotene. The preferred form of beta carotene is the naturally occurring form. The preferred amount is between 500 iu and 10,000 iu, and more preferably between 1500 iu and 7500 iu, and most preferably between about 1000 iu and 3000 iu.
  • Resverotrol is another important nutrient of the present invention. The preferred form of Resverotrol is from plan extract. The preferred amount of Resverotrol in the extract is from between 50% to about 98%, and most preferably about 95%. The preferred amount of Resverotrol extract to be employed in the present invention is from about 5 mg to about 1500 mg, and more preferably from about 50 mg to about 300 mg, and most preferably from about 75 mg to about 150 mg.
  • Additionally, Vitamin D3 may be added to the nutritional compositions of the present invention. The preferred form of Vitamin D3 is Cholecalciferol. The preferred amount of Vitamin D3 is from between 50 iu and 3000 iu, and more preferably between from about 70 iu to about 500 iu, and most preferably from about 100 iu to about 250 iu.
  • Another prime nutrient that may be included in the embodiments of the present invention is Vitamin K. The preferred form of Vitamin K is Phytonadione. The preferred amount of Vitamin K is between 2.5 mcg to about 250 mcg, more preferably from between 15 mcg to about 100 mcg, and most preferably between 20 mcg to about 75 mcg.
  • Another nutrient important to the efficacy of the present invention is Vitamin B6. The preferred form of Vitamin B6 is Pyridoxine hydrochloride. The preferred amount is between 0.1 mg to about 100 mg, most preferably between about 0.5 mg to about 25 mg, and most preferably from about 0.75 mg to about 10 mg.
  • Additionally, Vitamin B 12 may be included in the present invention. The preferred form of Vitamin B12 is Cyanocobalamin. The preferred amount of Vitamin B12 is between about 0.3 mcg to about 900 mcg, most preferably between about 0.75 mcg to about 50 mcg, and most preferably between 1 mcg and 10 mcg.
  • Another nutrient that is important to the present invention is Folic Acid. The preferred amount of Folic Acid is between about 25 mcg to about 1000 mcg, most preferably between about 100 mcg to about 750 mcg, and most preferably between 200 mcg and 400 mcg.
  • The mineral Zinc is important to include in the present invention. The preferred amount of Zinc is between about 0.65 mcg to about 4000 mcg, most preferably between about 1 mcg to about 400 mcg, and most preferably between 3 mcg and 50 mcg.
  • The mineral Chromium is important to include in the present invention. The preferred form of Chromium is from yeast. The preferred amount of Chromium is between about 30 mcg to about 3000 mcg, most preferably between about 50 mcg to about 500 mcg, and most preferably between 25 mcg and 100 mcg.
  • The mineral Molybdenum is important to include in the present invention. The preferred form of Molybdenum is from yeast. The preferred amount of Molybdenum is between about 2.5 mcg to about 1000 mcg, most preferably between about 10 mcg to about 130 mcg, and most preferably between 15 mcg and 60 mcg.
  • The amino acid glutamine is important to include in the present invention. The preferred amount of glutamine is between about 2.1 g to about 250 g, most preferably between about 11 g to about 135 g, and most preferably between 10 g and 50 g.
  • The amino acid arginine is important to include in the present invention. The preferred amount of argenine is between about 0.71 g to about 25 g, most preferably between about 3.0 g to about 15 g, and most preferably between 5 g and 13 g.
  • The amino acid taurine is important to include in the present invention. The preferred amount of taurine is between about 1.1 g to about 29 g, most preferably between about 2.3 g to about 15 g, and most preferably between 3 g and 11 g.
  • The amino acid lysine is important to include in the present invention. The preferred amount of taurine is between about 0.81 g to about 49 g, most preferably between about 5.3 g to about 35 g, and most preferably between 6 g and 18 g.
  • Another important nutrient is Coenzyme Q-10. The preferred amount of Coenzyme Q-10 is from about 30 mg to about 1000 mg, most preferably from between about 50 mg to 300 mg, and most preferably between about 60 mg to about 180 mg.
  • The following examples are illustrative only and do not limit the invention in any fashion.
    • Example 1
  • Ingredient Amount
    Fish Oil 70 mg
    Selenium (from Selenium yeast) 2500 mcg
    Beta Carotene 1000 iu
    Vitamin D3 100 iu
    Vitamin K 15 mcg
    Vitamin B6 0.5 mg
    Vitamin B12 1 mcg
    Folic Acid 250 mcg
    Zinc 5.0 mg
    Chromium 25 mcg
    Molybdenum 15 mcg
    Glutamine 20 g
    Argenine 5.1 g
    Taurine 3.2 g
    Lysine 7.3 g
    CoQ-10 50 mg
    Niacin 2.1 mg
    Riboflavin 600 mcg
    Thiamin 530 mcg
    Biotin 2 mg
    Calcium 200 mg
    Iron 3 mg
    Phosphourous 213 mg
    Iodine 35 mg
    Copper 500 mcg
    Manganese 570 mcg
    Inositol 1.2 g
    Sucrose 3.5 g
    Whey Protein Isolate 0.75 g
    Non-Fat Milk 0.2 g
    Rice Protien 0.23 g
    Calcium Caseinate 0.14 g
    Soy Lecithin 0.1 g
  • The above ingredients were admixed and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
    • Example 2
  • Ingredient Amount
    Fish Oil 70 mg
    Selenium (from Selenium yeast) 2500 mcg
    Beta Carotene 1000 iu
    Vitamin D3 100 iu
    Vitamin K 15 mcg
    Vitamin B6 0.5 mg
    Vitamin B12 1 mcg
    Folic Acid 250 mcg
    Iron 3 mg
    Phosphourous 213 mg
    Iodine 35 mg
    Copper 500 mcg
    Manganese 570 mcg
    Inositol 1.2 g
    Sucrose 3.5 g
    Whey Protein Isolate 0.75 g
    Non-Fat Milk 0.2 g
    Rice Protien 0.23 g
    Calcium Caseinate 0.14 g
    Soy Lecithin 0.1 g
  • The above ingredients were admixed and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
    • Example 3
  • Ingredient Amount
    Fish Oil 90 mg
    Selenium (from Selenium yeast) 2540 mcg
    Beta Carotene 1300 iu
    Vitamin D3 80 iu
    Vitamin K 15 mcg
    Vitamin B6 0.5 mg
    Vitamin B12 1 mcg
    Folic Acid 250 mcg
    Zinc 3.0 mg
    Chromium 25 mcg
    Molybdenum 25 mcg
    Glutamine 29 g
    Argenine 7.1 g
    Taurine 3.2 g
    Lysine 7.6 g
    CoQ-10 100 mg
    Manganese 570 mcg
    Inositol 2.7 g
    Sucrose 3.5 g
    Whey Protein Isolate 0.75 g
    Non-Fat Milk 0.2 g
    Rice Protien 0.23 g
    Calcium Caseinate 0.14 g
    Soy Lecithin 0.1 g
  • The above ingredients were admixed and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
    • Example 4
  • Ingredient Amount
    Fish Oil 110 mg
    Selenium (from Selenium yeast) 1500 mcg
    Beta Carotene 200 iu
    Vitamin D3 100 iu
    Vitamin K 15 mcg
    Vitamin B6 0.5 mg
    Vitamin B12 1 mcg
    Folic Acid 250 mcg
    Zinc 5.0 mg
    Chromium 25 mcg
    Molybdenum 15 mcg
    Glutamine 20 g
    Argenine 5.1 g
    Taurine 3.2 g
    Lysine 7.3 g
    CoQ-10 50 mg
    Niacin 2.1 mg
    Riboflavin 600 mcg
    Thiamin 530 mcg
    Biotin 2 mg
    Calcium 200 mg
    Iron 3 mg
    Phosphourous 213 mg
    Iodine 35 mg
    Copper 500 mcg
    Manganese 570 mcg
    Inositol 1.2 g
    Sucrose 3.5 g
    Whey Protein Isolate 0.75 g
    Non-Fat Milk 0.2 g
    Rice Protien 0.23 g
    Calcium Caseinate 0.14 g
    Soy Lecithin 0.1 g
  • The above ingredients were admixed and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
    • Example 5
  • Ingredient Amount
    Fish Oil 90 mg
    Selenium (from Selenium yeast) 1560 mcg
    Beta Carotene 900 iu
    Vitamin D3 92 iu
    Vitamin K 23 mcg
    Vitamin B6 5.5 mg
    Vitamin B12 3 mcg
    Folic Acid 250 mcg
    Zinc 6.0 mg
    Chromium 25 mcg
    Molybdenum 15 mcg
    Glutamine 23 g
    Argenine 5.1 g
    Taurine 2.2 g
    Lysine 7.3 g
    CoQ-10 50 mg
    Niacin 2.1 mg
    Riboflavin 600 mcg
    Thiamin 530 mcg
    Biotin 2 mg
    Calcium 200 mg
    Iron 3 mg
    Phosphourous 213 mg
    Iodine 35 mg
    Copper 500 mcg
    Manganese 570 mcg
    Inositol 1.2 g
    Sucrose 3.5 g
    Whey Protein Isolate 0.75 g
    Non-Fat Milk 0.2 g
    Rice Protien 0.23 g
    Calcium Caseinate 0.14 g
    Soy Lecithin 0.1 g
  • The above ingredients were admixed and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.
    • Example 6
  • Ingredient Amount
    Fish Oil 70 mg
    Selenium (from Selenium yeast) 2500 mcg
    Beta Carotene 1000 iu
    Vitamin D3 100 iu
    Vitamin K 15 mcg
    Vitamin B6 0.5 mg
    Vitamin B12 1 mcg
    Folic Acid 250 mcg
    Zinc 5.0 mg
    Chromium 25 mcg
    Molybdenum 15 mcg
    Glutamine 20 g
    Argenine 5.1 g
    Taurine 3.2 g
    Lysine 7.3 g
    CoQ-10 50 mg
    Biotin 2 mg
    Calcium 200 mg
    Iron 3 mg
    Phosphourous 213 mg
    Iodine 35 mg
    Copper 500 mcg
    Manganese 570 mcg
    Inositol 1.2 g
    Sucrose 3.5 g
    Whey Protein Isolate 0.75 g
    Rice Protein 0.23 g
    Calcium Caseinate 0.14 g
    Soy Lecithin 0.1 g
  • The above ingredients were admixed and shaken until homogeneous blend was obtained. The blended composition was poured into 250 mL of water, mixed and then consumed via drinking.

Claims (14)

What is claimed is:
1. A nutritional composition suitable for oral consumption by the human system comprising selenium in the form of selenium yeast together with a fish oil preparation.
2. The composition of claim 1 with Resverotrol extract.
3. The composition of claim 2 with naturally occurring Beta-carotene preparation.
4. The composition of claim 3 with vitamin D3.
5. The composition of claim 4 with the vitamin K, vitamin B6, folic acid, and Coenzyme Q-10.
6. The composition of claim 5 with the addition of the minerals Zinc, Chromium, Molybdenum.
7. The composition of claim 6 with the addition of the amino acids Glutamine, Argenine, Taurine, Lysine.
8. A nutritional composition suitable for oral consumption by the human system comprising selenium in the form of selenium yeast having from between 25 mg to 150 mcg of selenium yeast preparation together with a fish oil preparation of between 350 mg to 750 mg, comprising 30%-65% of the fatty acids EPA and DHA where the preferred ratio of EPA to DHA is about 3 parts EPA to 2 parts DHA.
9. The composition of claim 8 with Resverotrol extract, where the amount of the Resverotrol extract is between about 50 mg-150 mg.
10. The composition of claim 9 with naturally occurring Beta-carotene preparation comprising from 1000 iu to 3000 iu.
11. The composition of claim 10 with addition of 100 iu to 25 iu of vitamin D3.
12. The composition of claim 11 with the addition of vitamin K, vitamin B6, folic acid, and Coenzyme Q-10.
13. The composition of claim 12 with the addition of the minerals Zinc, Chromium, Molybdenum.
14. The composition of claim 13 with the addition of the amino acids Glutamine, Argenine, Taurine, Lysine.
US13/852,472 2013-03-28 2013-03-28 Nutritional Composition Abandoned US20140294795A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US13/852,472 US20140294795A1 (en) 2013-03-28 2013-03-28 Nutritional Composition
US15/205,786 US10117902B2 (en) 2013-03-28 2016-07-08 Nutritional composition
US16/156,990 US10653733B2 (en) 2013-03-28 2018-10-10 Nutritional composition
US16/875,805 US10946052B2 (en) 2013-03-28 2020-05-15 Nutritional composition
US17/200,056 US11253561B2 (en) 2013-03-28 2021-03-12 Nutritional composition
US17/675,181 US11576940B2 (en) 2013-03-28 2022-02-18 Nutritional composition
US18/079,155 US12029769B2 (en) 2013-03-28 2022-12-12 Nutritional composition
US18/763,681 US20240350569A1 (en) 2013-03-28 2024-07-03 Nutritional Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/852,472 US20140294795A1 (en) 2013-03-28 2013-03-28 Nutritional Composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/205,786 Division US10117902B2 (en) 2013-03-28 2016-07-08 Nutritional composition

Publications (1)

Publication Number Publication Date
US20140294795A1 true US20140294795A1 (en) 2014-10-02

Family

ID=51621073

Family Applications (8)

Application Number Title Priority Date Filing Date
US13/852,472 Abandoned US20140294795A1 (en) 2013-03-28 2013-03-28 Nutritional Composition
US15/205,786 Active US10117902B2 (en) 2013-03-28 2016-07-08 Nutritional composition
US16/156,990 Active US10653733B2 (en) 2013-03-28 2018-10-10 Nutritional composition
US16/875,805 Active US10946052B2 (en) 2013-03-28 2020-05-15 Nutritional composition
US17/200,056 Active US11253561B2 (en) 2013-03-28 2021-03-12 Nutritional composition
US17/675,181 Active US11576940B2 (en) 2013-03-28 2022-02-18 Nutritional composition
US18/079,155 Active US12029769B2 (en) 2013-03-28 2022-12-12 Nutritional composition
US18/763,681 Pending US20240350569A1 (en) 2013-03-28 2024-07-03 Nutritional Composition

Family Applications After (7)

Application Number Title Priority Date Filing Date
US15/205,786 Active US10117902B2 (en) 2013-03-28 2016-07-08 Nutritional composition
US16/156,990 Active US10653733B2 (en) 2013-03-28 2018-10-10 Nutritional composition
US16/875,805 Active US10946052B2 (en) 2013-03-28 2020-05-15 Nutritional composition
US17/200,056 Active US11253561B2 (en) 2013-03-28 2021-03-12 Nutritional composition
US17/675,181 Active US11576940B2 (en) 2013-03-28 2022-02-18 Nutritional composition
US18/079,155 Active US12029769B2 (en) 2013-03-28 2022-12-12 Nutritional composition
US18/763,681 Pending US20240350569A1 (en) 2013-03-28 2024-07-03 Nutritional Composition

Country Status (1)

Country Link
US (8) US20140294795A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067604A1 (en) * 2016-10-03 2018-04-12 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
WO2018231937A2 (en) 2017-06-13 2018-12-20 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
IT201700104446A1 (en) * 2017-09-19 2019-03-19 Lo Li Pharma Srl Compositions, uses and methods for the treatment of infertility and subfertility
CN111479578A (en) * 2017-06-13 2020-07-31 夏滉 Compositions and methods for enhancing hyperthermia
JP2020523370A (en) * 2017-06-13 2020-08-06 シャー, ホウン・サイモンHsia, Houn Simon Compositions and methods for enhancing cancer chemotherapy
CN114072155A (en) * 2019-04-01 2022-02-18 豪恩·西蒙·夏 Compositions and methods for cancer immunotherapy
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140294795A1 (en) 2013-03-28 2014-10-02 Houn Simon Hsia Nutritional Composition
CN108378377A (en) * 2018-05-08 2018-08-10 山东理工大学 The preparation method and applications of cervical carcinoma full nutrition formula food
EP4595776A1 (en) 2024-02-02 2025-08-06 Giuseppe Pasqualetti Nutritional composition for cancer patients and elderly subjects

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007607A1 (en) * 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer
US6197295B1 (en) * 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US6440464B1 (en) * 1996-06-10 2002-08-27 Viva Life Science Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
US6605296B1 (en) * 1998-03-24 2003-08-12 Numico Research B.V. Natural substances based agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976548A (en) * 1994-11-08 1999-11-02 Viva America Marketing, Inc. Nutritional supplement composition and use
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
WO2006035416A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Minicapsule formulations
US8017147B2 (en) * 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
US20140294795A1 (en) 2013-03-28 2014-10-02 Houn Simon Hsia Nutritional Composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440464B1 (en) * 1996-06-10 2002-08-27 Viva Life Science Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
US6197295B1 (en) * 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US6605296B1 (en) * 1998-03-24 2003-08-12 Numico Research B.V. Natural substances based agent
WO2000007607A1 (en) * 1998-08-04 2000-02-17 Kosbab, John, V. Nutrient and therapeutic compositions for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ben-Amotz et al., Bioavailability of a natural isomer mixture compared with synthetic all-trans beta-carotene in human serum, 1996, The American Journal of Clinical Nutrition 63(5): 729-734. *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067604A1 (en) * 2016-10-03 2018-04-12 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
US12035739B2 (en) 2016-10-03 2024-07-16 Houn Simon Hsia Compositions and methods for reducing cancer stem cell growth
JP7465313B2 (en) 2016-10-03 2024-04-10 シャー，ホウン・サイモン Compositions and methods for enhancing cancer radiation therapy - Patents.com
JP2022160655A (en) * 2016-10-03 2022-10-19 シャー，ホウン・サイモン Compositions and methods for enhancing cancer radiotherapy
JP7123945B2 (en) 2016-10-03 2022-08-23 シャー，ホウン・サイモン Compositions and methods for enhancing cancer radiotherapy
KR20190067828A (en) * 2016-10-03 2019-06-17 호운 사이먼 샤 Compositions and methods for improving cancer radiation therapy
CN110312439A (en) * 2016-10-03 2019-10-08 夏滉 For enhancing the composition and method of cancer radiation therapy
JP2019529578A (en) * 2016-10-03 2019-10-17 シャー, ホウン・サイモンHsia, Houn Simon Compositions and methods for enhancing cancer radiotherapy
KR102402485B1 (en) 2016-10-03 2022-05-25 호운 사이먼 샤 Compositions and methods for enhancing cancer radiotherapy
US11206861B2 (en) 2016-10-03 2021-12-28 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
CN111479578A (en) * 2017-06-13 2020-07-31 夏滉 Compositions and methods for enhancing hyperthermia
WO2018231937A3 (en) * 2017-06-13 2019-03-28 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
JP2020523370A (en) * 2017-06-13 2020-08-06 シャー, ホウン・サイモンHsia, Houn Simon Compositions and methods for enhancing cancer chemotherapy
JP2020523374A (en) * 2017-06-13 2020-08-06 シャー, ホウン・サイモンHsia, Houn Simon Compositions and methods for enhancing cancer radiotherapy
CN111556754A (en) * 2017-06-13 2020-08-18 夏滉 Compositions and methods for enhancing cancer chemotherapy
US10905723B2 (en) 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
US10905724B2 (en) 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing hyperthermia therapy
US10905725B2 (en) 2017-06-13 2021-02-02 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
EP3638247A4 (en) * 2017-06-13 2021-03-03 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
EP3638270A4 (en) * 2017-06-13 2021-06-30 Houn Simon Hsia COMPOSITIONS AND METHODS FOR IMPROVING HYPERTHERMIA TREATMENT
CN111479577A (en) * 2017-06-13 2020-07-31 夏滉 Compositions and methods for enhancing cancer radiotherapy
KR102775757B1 (en) * 2017-06-13 2025-02-28 호운 사이먼 샤 Compositions and methods for improving cancer radiotherapy
IL271327B2 (en) * 2017-06-13 2024-11-01 Simon Hsia Houn Compositions for increasing tumor sensitivity to hyperthermic treatment
KR20200078467A (en) * 2017-06-13 2020-07-01 호운 사이먼 샤 Compositions and methods for improving cancer radiotherapy
WO2018231937A2 (en) 2017-06-13 2018-12-20 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy
US12036246B2 (en) 2017-06-13 2024-07-16 Houn Simon Hsia Compositions and methods for enhancing cancer chemotherapy
US11433105B2 (en) 2017-06-13 2022-09-06 Houn Simon Hsia Compositions and methods for enhancing hyperthermia therapy
US12029765B2 (en) 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
IL271327B1 (en) * 2017-06-13 2024-07-01 Simon Hsia Houn Compositions for increasing tumor sensitivity to hyperthermic treatment
US11541079B2 (en) 2017-06-13 2023-01-03 Houn Simon Hsia Compositions and methods for enhancing cancer immunotherapy
JP2023105154A (en) * 2017-06-13 2023-07-28 シャー，ホウン・サイモン Use of a sensitizer for the preparation of a medicament for modulating the content of pAMPKα or COX-2 in cancer cells
JP2023105153A (en) * 2017-06-13 2023-07-28 シャー，ホウン・サイモン Nutritional supplement containing fish oil and selenium
JP2023115357A (en) * 2017-06-13 2023-08-18 シャー，ホウン・サイモン Compositions and methods for enhancing cancer chemotherapy
JP7336993B2 (en) 2017-06-13 2023-09-01 シャー，ホウン・サイモン Compositions and methods for enhancing cancer radiotherapy
US11896624B2 (en) 2017-06-13 2024-02-13 Houn Simon Hsia Compositions for enhancing hyperthermia therapy
IT201700104446A1 (en) * 2017-09-19 2019-03-19 Lo Li Pharma Srl Compositions, uses and methods for the treatment of infertility and subfertility
KR102468673B1 (en) * 2017-09-19 2022-11-17 로.리. 파르마 에스.알.엘 Compositions, uses and methods for infertility and infertility treatment
WO2019057709A1 (en) * 2017-09-19 2019-03-28 Lo.Li Pharma S.R.L. Compositions, uses and methods for treatment of infertility and subfertility
KR20200092939A (en) * 2017-09-19 2020-08-04 로.리. 파르마 에스.알.엘 Compositions, uses and methods for treating infertility and infertility
US11364282B2 (en) * 2017-09-19 2022-06-21 Lo.Li. Pharma S.R.L. Compositions, uses and methods for treatment of infertility and subfertility
US20220062388A1 (en) * 2017-09-19 2022-03-03 Lo.Li. Pharma S.R.L. Compositions, uses and methods for treatment of infertility and subfertility
CN114072155A (en) * 2019-04-01 2022-02-18 豪恩·西蒙·夏 Compositions and methods for cancer immunotherapy

Also Published As

Publication number Publication date
US10117902B2 (en) 2018-11-06
US20190038687A1 (en) 2019-02-07
US20160317593A1 (en) 2016-11-03
US10946052B2 (en) 2021-03-16
US20200276254A1 (en) 2020-09-03
US11253561B2 (en) 2022-02-22
US20210283205A1 (en) 2021-09-16
US12029769B2 (en) 2024-07-09
US11576940B2 (en) 2023-02-14
US20240350569A1 (en) 2024-10-24
US10653733B2 (en) 2020-05-19
US20220168369A1 (en) 2022-06-02
US20230113424A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US11576940B2 (en) Nutritional composition
US20090110674A1 (en) Health supplement
US6471969B1 (en) Two-phase preparation
CN107821602A (en) Nutrient formulation powder that a kind of suitable muscle decay crowd eats and preparation method thereof
JP2021503878A (en) Compositions and Methods Using Oleuropein or Curcumin for Muscle Quality and / or Muscle Mass
US10342845B1 (en) Diabetic nutritional composition
US8197871B2 (en) Composition for headache treatment
TWI612905B (en) A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
JP4102820B2 (en) Dietary supplements and related methods
Laila et al. Camel milk as a potential nutritional therapy in autism
RU2685883C1 (en) Vitaminized drinking water
US20150147305A1 (en) Asthmatic and Allergenic Nutritional Composition
RU2751190C1 (en) Anti-stress drink
US20220323535A1 (en) Health supplement
Nieto et al. Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review
RU2837268C1 (en) Enteral nutrition composition
Van Schoor Boosting your immune system
US8889157B1 (en) Composition for cardiovascular treatment
CN105219606A (en) A kind of loquat fruit wine
RU2847880C1 (en) Concentrated drink "stomach"
Nyzhnyk et al. PECULIARITIES OF THE EFFECT OF VITAMINS ON THE BODY OF AN ELDERLY PERSON
Pelton et al. Microbiome-Disrupting Drugs
Smith et al. Role of Spirulina in Anemia Management and Hematopoiesis
Story et al. A clinician’s perspective on antioxidant use during chemotherapy for breast cancer: exploring the evidence
RU2585478C1 (en) Method for development of formulation product compensating for individual deficiency of vitamins and mineral substances in body

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION